Furthermore, we demonstrated the tumor types that were most suitable for PET/CT imaging with 68Ga-MY6349 and presented the potential clinical indications for the future use of Trop2-targeted PET/CT, along with a quantitative analysis of lesions in patients with breast cancer before and after treatment with Trop2-targeted ADC drugs. Here, TACSTD2 is linked to breast cancer.